共 30 条
- [21] Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA)STROKE, 2006, 37 (02) : 695 - 695Poulter, NRDahlof, BSever, PSWedel, HCollier, D
- [22] LONG-TERM OUTCOMES OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV VIA A COST-EFFECTIVENESS MODELVALUE IN HEALTH, 2022, 25 (07) : S379 - S379Vardanega, V.Rawlinson, W.Francis-Graham, S.Mezzio, D.Eddowes, L. A.
- [23] Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin A Cohort Analysis From the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering ArmJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (08) : 717 - 729Sever, Peter S.Poulter, Neil R.Chang, Choon L.Thom, Simon A. M.Hughes, Alun D.Welsh, PaulSattar, Naveed
- [24] Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled TrialDrugs, 2004, 64 : 43 - 60Peter S SeverBjörn DahlöfNeil R PoulterHans WedelGareth BeeversMark CaulfieldRory CollinsSverre E KjeldsenArni KristinssonGordon T McInnesJesper MehlsenMarkku NieminenEoin O’BrienJan Östergren
- [25] Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -: Lipid lowering arm (ASCOT-LLA):: A multicentre randomised controlled trialDRUGS, 2004, 64 (Suppl 2) : 43 - 60Sever, PSDahlöf, BPoulter, NRWedel, HBeevers, GCaulfield, MCollins, RKjeldsen, SEKristinsson, AMcInnes, GTMehlsen, JNieminen, MO'Brien, EÖstergren, J
- [26] Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trialLANCET, 2003, 361 (9364): : 1149 - 1158Sever, PSDahlöf, BPoulter, NRWedel, HBeevers, GCaulfield, MCollins, RKjeldsen, SEKristinsson, AMcInnes, GTMehlsen, JNieminen, MO'Brien, EÖstergren, J
- [27] Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]JOURNAL OF INTERNAL MEDICINE, 2005, 258 (04) : 336 - 343Nadar, SKBlann, ABeevers, DGLip, GYH
- [29] Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trialLANCET GLOBAL HEALTH, 2022, 10 (12): : E1845 - E1854Lawrence, David S.Muthoga, CharlesMeya, David B.Tugume, LillianWilliams, DarlishaRajasingham, RadhaBoulware, David R.Mwandumba, Henry C.Moyo, MelanieDziwani, Eltas N.Maheswaran, HendramoorthyKanyama, CeciliaHosseinipour, Mina C.Chawinga, ChimwemweMeintjes, GraemeSchutz, CharlotteComins, KylaBango, FunekaMuzoora, ConradJjunju, SamuelNuwagira, EdwinMosepele, MosepeleLeeme, TshepoNdhlovu, Chiratidzo E.Hlupeni, AdmireShamu, ShepherdBoyer-Chammard, TimotheeMolloy, Sile F.Youssouf, NabilaChen, TaoShiri, TinevimboJaffar, ShabbarHarrison, Thomas S.Jarvis, Joseph N.Niessen, Louis W.